Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Andrew W. Roberts(The Royal Melbourne Hospital), Michael Hallek(Integrated Oncology (United States)), Relja Popovic(Loyola University Medical Center), Matthew S. Davids(Dana-Farber Cancer Institute), Brenda Chyla(AbbVie (United States)), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), Michael Y. Choi(University of California San Diego), John F. Seymour(The Royal Melbourne Hospital), Ming Zhu(AbbVie (United States)), Barbara Eichhorst(University of Cologne), Jalaja Potluri(AbbVie (United States)), Su Young Kim(AbbVie (United States)), Stephan Stilgenbauer(Universität Ulm), Maria Verdugo(AbbVie (United States)), Leanne Lash(AbbVie (United States))
Cited by 14
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k